1stOncology™: Cancer Intelligence Service – Page 7274 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference

On March 2, 2022 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion focused on cell therapy at the Cowen 42nd Annual Virtual Healthcare Conference on Wednesday, March 9, 2022, at 9:10 a.m. EST (Press release, Atara Biotherapeutics, MAR 2, 2022, View Source [SID1234609360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the panel will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

Supernus to Participate in Annual Cowen Health Care Conference

On March 2, 2022 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat as part of the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 1:30 p.m. ET (Press release, Supernus, MAR 2, 2022, View Source [SID1234609359]).

A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay will be available for 60 days on the Company’s website following the conference.

Protara Therapeutics to Participate in Upcoming Investor Conferences

On March 2, 2022 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported that management will participate in fireside chats at two upcoming virtual conferences (Press release, Protara Therapeutics, MAR 2, 2022, View Source [SID1234609358]):

Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10am ET
Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022 at 2:00pm ET
A live webcast of the fireside chats can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcasts will be archived on the Company’s website for 90 days following the presentations.

SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

On March 2, 2022 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported its participation in three in-person medical conferences and one virtual investor panel in March (Press release, Scynexis, MAR 2, 2022, View Source [SID1234609356]). Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a live panel discussion on drug development in Women’s Health. Event details can be found below:

Conferences:

International Society for the Study of Women’s Sexual Health (ISSWSH)
Date: March 3-6, 2022
Location: Dallas
Event Page
Council on Resident Education in Obstetrics and Gynecology (CREOG) & Association of Professors of Gynecology and Obstetrics (APGO) Annual Meeting
Date: March 9-12, 2022
Location: Orlando
Event Page
Academy of Managed Care Pharmacy (AMCP)
Date: March 29- April 1, 2022
Location: Chicago
Event Page
Virtual Investor Panel:

Maxim Group’s Annual Growth Conference
Panel: Women’s Health Virtual Event
Date: March 28, 2022
Location: Virtual
Time: 3:00 p.m. ET
Event Page

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

On March 2, 2022 Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana (Press release, Aravive, MAR 2, 2022, View Source [SID1234609352]). The abstract presentation at AACR (Free AACR Whitepaper) will be presented virtually.

Presentation Details
Title: Exposure-Response Analysis of Batiraxcept and Application to Recommended Phase 2 Dose in Platinum-Resistant Ovarian and Clear Cell Renal Cancers
Abstract Number: 7867
Presentation Type: Remote Poster Presentation
Date: April 8, 2022